- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
From Benzinga
From Benzinga
Earnings Scheduled For April 29, 2022
April 29, 2022
From Benzinga
Pandemic is not over yet, says Dr. Fauci, and WHO says omicron accounted for 99.7% of all cases sequenced in latest week
April 28, 2022
From MarketWatch
From Benzinga
From Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
April 27, 2022
From Benzinga
From Benzinga
3 Biotech Stocks Under $10 to Add to Your Buy List
April 26, 2022
From InvestorPlace
From MarketWatch
Valneva Receives More Questions From European Regulator For Its COVID-19 Vaccine, Shares Fall
April 25, 2022
From Benzinga
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer
April 25, 2022
From Benzinga
From Motley Fool
2 Dividend Stocks to Buy and Hold Forever
April 22, 2022
From Motley Fool
World's Largest Vaccine Manufacturer Stops Making COVID-19 Vaccines As 200M Doses Pile-Up: Bloomberg
April 22, 2022
From Benzinga
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
April 22, 2022
From Benzinga
2 Charts Big Pharma Investors Need to Understand
April 21, 2022
From Motley Fool
If You Invested $100 In AstraZeneca 5 Years Ago, Here's How Much You Would Have Today
April 21, 2022
Tickers
AZN
From Benzinga
From Benzinga
From Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
From InvestorPlace
AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals
April 21, 2022
From Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
April 20, 2022
From InvestorPlace
From Benzinga
From Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
April 19, 2022
From Benzinga
Why Nektar Therapeutics Stock Is Crashing Today
April 18, 2022
From Motley Fool
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.